Blood test may cut unnecessary scans for breast cancer patients

NCT ID NCT04968964

Recruiting now Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tests whether a blood test called DiviTum TKa can help doctors decide to order fewer scans and other tests for women with HR+ HER2- metastatic breast cancer. The trial will enroll 55 women starting a common first-line treatment. Doctors will fill out care plans before and after seeing the blood test results to see if they change their testing plans. The goal is to reduce the burden of frequent testing without missing disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DiviTum® TKa assay (blood test measuring TK1 activity)
What this could lead to: If successful, this could help doctors rely more on a simple blood test and reduce the number of scans and other tests needed to monitor metastatic breast cancer.
What could go wrong: This is a small, early study (55 people) that only looks at whether doctors change their testing plans. It does not directly measure patient outcomes, so the real benefit is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CANCER OF THE BREAST

Contacts and locations

Locations

Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.